Trial Profile
Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Idarubicin; Mitoxantrone
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 20 Nov 2023 Planned End Date changed from 31 Oct 2025 to 22 Sep 2024.
- 17 Nov 2021 Planned End Date changed from 1 Apr 2023 to 31 Oct 2025.
- 06 Nov 2020 Status changed from completed to active, no longer recruiting.